Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis

Diagn Microbiol Infect Dis. 2004 Dec;50(4):247-51. doi: 10.1016/j.diagmicrobio.2004.07.011.

Abstract

Because human infections by Scedosporium prolificans are difficult to treat and show a very poor outcome, new therapeutic strategies are needed. Liposomal amphotericin B (LAMB) (40 mg/kg/day) increased significantly the mean survival time in immunosuppressed mice compared with a control group (22.6 vs. 8.8 days). Amphotericin B deoxycholate (1.5 mg/kg/day) and granulocyte colony-stimulating factor (G-CSF) (300 microg/kg/day) were ineffective. The combination of LAMB (40 mg/kg/day) and G-CSF (150 or 300 microg/kg/day) did not improve the results obtained with LAMB alone.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Therapy, Combination
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Immunocompromised Host
  • Liposomes
  • Lymphocyte Count
  • Male
  • Mice
  • Mice, Inbred Strains
  • Mycetoma / drug therapy*
  • Scedosporium*

Substances

  • Antifungal Agents
  • Liposomes
  • liposomal amphotericin B
  • Granulocyte Colony-Stimulating Factor
  • Amphotericin B